Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 11 - Drugs for disorders of the respiratory system
Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767)
05/2005
05/31/2005US6900336 8-aza-11-deoxy prostaglandin analogues
05/31/2005US6900334 Antiallergens; autoimmune diseases
05/31/2005US6900309 Aminocarbonylation reaction of a adenosine compound containing purine base and pentofuranosyl sugar and a leaving group at 2 position of purine ring, with an amine compound in presence of carbon monoxide and suitable coupling catalyst
05/31/2005US6900243 Phenylheteroalkylamine derivatives
05/31/2005US6900216 Psychological disorders; antidepressants; brain diosrders; anticonvulsants
05/31/2005US6900211 CCR5 antagonists useful for treating aids
05/31/2005US6900201 N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
05/31/2005US6900194 Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors for the treatment of respiratory diseases
05/31/2005US6900043 Phosphatases which activate map kinase pathways
05/31/2005US6899869 Method of preparing an animal model for interstitial pneumonia
05/26/2005WO2003004039A9 Composition comprising soy and use thereof in the prevention and/or treatment of various diseases
05/26/2005US20050114914 linker for activation of T- cells (lat genes and proteins), used for screening drug useful for treatment against asthma and allergies
05/26/2005US20050113577 Such as hydrochloride salt 3-[5-(4-methanesulfonyl-piperazin-1-yl-methyl)-1H-indol-2-yl]-1H-quinolin-2-one; signal transduction; for treatment of angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, and inflammatory diseases
05/26/2005US20050113451 7-acetamidinyl derivatives
05/26/2005US20050113447 Selective retinoid agonists
05/26/2005US20050113443 Modulation of airway inflammation in patients with cystic fibrosis and related diseases
05/26/2005US20050113416 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods
05/26/2005US20050113414 1-[1-((E)-1-Cyclooct-1-enyl)methylpiperidin-4-yl]-3-(3,4-dichlorophenyl)-urea; potent and selective modulators of CXCR3, a chemokine receptor; antagonists; treatment of conditions involving inappropriate T-cell trafficking; antiinflammatory, -arthritic agents, autoimmune diseases; antiallergens
05/26/2005US20050113402 Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
05/26/2005US20050113383 For therapy of allergy, allergy-induced airway responses, congestion, hypotension, cardiovascular disease, hypotension, diseases of the GI tract, hyper and hypo motility and acidic secretion of the gastrointestinal tract, obesity, sleep
05/26/2005US20050113377 2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase, 2 (COX-2) inhibitors
05/26/2005US20050113361 Amide derivatives as NMDA receptor antagonists
05/26/2005US20050113360 NMDA (N-methyl-D-aspartate) receptors; eg 6-(4-benzylpiperidin-1-carbonyl)-1,5-dihydro-oxazolo[4,5-f]indole-2-one
05/26/2005US20050113359 NMDA (N-methyl-D-aspartate) receptors; eg 1-[4-(4-fluoro-benzyl)-piperidin-1-yl]-1-(6-hydroxy-1H-indole-2-yl)methanone
05/26/2005US20050113358 Enzyme inhibitors for erectile dysfunction and sexual disorders
05/26/2005US20050113299 Protein a compositions and methods of use
05/26/2005US20050113291 Use of a substance which binds to and initiates signaling of the human SARP-1 receptor or a substance which stimulates release or potentiates the activity of endogenous SARP-1 for the manufacture of a medicament for the treatment and/or prevention of scleroderma, in particular of systemic sclerosis
05/26/2005US20050113284 Drug for regenerating tissue and vessel and method therefor
05/26/2005US20050112725 Secreted and transmembrane polypeptides and nucleic acids encoding the same
05/26/2005US20050112565 Proteases
05/26/2005US20050112206 Mixture of drug, aminoacrylate polymer and acid
05/26/2005US20050112092 Stable, aerosolizable suspensions of proteins in ethanol
05/26/2005US20050112069 Pharmaceutical composition of a pde4 or pde 3/4 inhibitor and histamine receptor antagonist
05/26/2005CA2545364A1 Methods of modulating angiogenesis and cancer cell proliferation
05/26/2005CA2545325A1 Compositions for reducing bacterial carriage and cns invasion and methods of using same
05/26/2005CA2545060A1 Methods of use of thrombin receptor antagonists
05/25/2005EP1533313A1 Novel derivative of flavone c-glycoside and composition containing the same
05/25/2005EP1533294A1 Beta-alanine derivative and use thereof
05/25/2005EP1532986A2 Pharmaceutical composition for treatment of rhinitis
05/25/2005EP1532242A2 Methods for preparing purified prostaglandin e synthase
05/25/2005EP1532238A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
05/25/2005EP1532172A2 Immunogenic composition comprising an il-13 element and t cell epitopes, and itstherapeutic use
05/25/2005EP1532148A1 Novel purine- or pyrrolol(2,3-d)pyrimidine-2-carbonitiles for treating diseases associated with cysteine protease activity
05/25/2005EP1532145A1 Pyrazole compositions useful as inhibitors of gsk-3
05/25/2005EP1532144A1 Novel quinuclidine derivatives and their use
05/25/2005EP1532135A1 Nf-kb inhibitors
05/25/2005EP1532133A1 Nf-:b inhibitors
05/25/2005EP1532121A1 New use of pyrimidine - or triazine- 2-carbonitiles for treating diseases associated with cysteine protease activity and novel pyrimidine-2-carbonitile derivatives
05/25/2005EP1532111A1 2,5-disubstituted 3-mercaptopentanoic acid
05/25/2005EP1532104A1 Crystalline beta-2 adrenergic receptor agonist
05/25/2005EP1531866A1 Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids
05/25/2005EP1531861A2 Mycoplasma gallisepticum formulation
05/25/2005EP1531834A1 Antisense compounds, methods and compositions for treating ngal-related inflammatory disorders
05/25/2005EP1531833A1 Antisense compounds, methods and compositions for treating mmp-12 related inflammatory disorders
05/25/2005EP1531830A1 Method for reducing c-rective protein levels with non-antibacterial tetracycline formulations
05/25/2005EP1531812A1 Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthristis
05/25/2005EP1531808A1 Peroxynitrite rearrangement catalysts used for the treatment or prophylaxis of diseases caused by peroxynitrite-mediated reactions
05/25/2005EP1531806A2 Use of thio-oxindole derivatives in treatment of hormone-related conditions
05/25/2005EP1531802A1 Pharmaceutical formulations comprising combinations of epinastine, pseudoephedrine and methylephedrine
05/25/2005EP1531795A1 Formulations limiting spread of pulmonary infections
05/25/2005EP1341791B1 Thioether substituted imidazoquinolines
05/25/2005EP1287137B1 REGULATION OF HUMAN $g(a)1A?ADRENERGIC RECEPTOR-LIKE G PROTEIN-COUPLED RECEPTOR
05/25/2005EP1282592B1 Use of amines
05/25/2005EP1261333B1 Use of topiramate for the treatment and diagnosis of sleep disordered breathing and means for carrying out the treatment and diagnosis
05/25/2005EP1163335B1 MATERIALS AND METHODS RELATING TO MODULATION OF p66 EXPRESSION
05/25/2005EP1039911B1 MORPHOLINO-N-ETHYL ESTER PRODRUGS OF INDOLE sPLA 2 INHIBITORS
05/25/2005EP0907652B1 Immunosuppressive compounds and methods
05/25/2005EP0888541B1 Cryptic peptides and method for their identification
05/25/2005EP0880362B1 Compositions comprising a cyclooxygenase-2 inhibitor and a leukotriene b 4 receptor antagonist
05/25/2005CN1620500A Corona-virus-like particles comprising functionally deleted genomes
05/25/2005CN1620467A Secreted protein
05/25/2005CN1620461A 2-amino-propanol derivatives
05/25/2005CN1620459A 稠合双环嘧啶衍生物 Fused bicyclic pyrimidine derivative
05/25/2005CN1620458A 噻吩并嘧啶 Thienopyrimidine
05/25/2005CN1620451A Benzhydryl derivatives
05/25/2005CN1620435A 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
05/25/2005CN1620434A Pyrrolidine-2-ones as factor Xa inhibitors
05/25/2005CN1620433A Pyrrolidine derivatives as inhibitors of endothelin-converting enzyme
05/25/2005CN1620431A (20s)-1alpha-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
05/25/2005CN1620424A Compounds for the treatment of inflammatory disorders
05/25/2005CN1620414A 维生素d类似物 Vitamin d analogues
05/25/2005CN1620309A Novel pharmaceutical composition of interferon gamma or pirfenidone with molecular diagnostics for the improved treatment of interstitial lung diseases
05/25/2005CN1620303A Skin perparation for external use containing purpuricenus temminckii frass as the active ingredient
05/25/2005CN1620299A Alpha-hydroxy-2-methylene-10-nor-pregnacalciferol and its uses
05/25/2005CN1620294A Pyrimidine A2b selective antagonist compounds, their synthesis and use
05/25/2005CN1618969A Mammalian sytokine-like polypeptide-10
05/25/2005CN1618802A Tetramer combined with SARS antigen peptide and its preparation and use
05/25/2005CN1618463A Composite prepns. for treating and preventing SARS
05/25/2005CN1618450A Medicine for treating chronic bronchitis and bronchial asthma
05/25/2005CN1618444A Composite biological liquor for cleaning toxins (or clearing lung and eliminating toxin biological liquor), and its prepn. method
05/25/2005CN1618435A Oral liquor for promoting-blood circulation and removing blood stasis contg. Radix astragali and ginseng
05/25/2005CN1618431A Dispersion tablet contg. Gynostemma petaphylla total glucosides, and its prepn. method
05/25/2005CN1203070C Thrombin receptor antagonists
05/25/2005CN1203069C Substituted piperidines, medicaments containing these compounds, and methods for production thereof
05/25/2005CN1203058C Piperidine derivatives and drugs containing these derivatives as active ingredient
05/25/2005CN1203049C Rapid-dissolved ambroxol salt and preparing method thereof
05/25/2005CN1202865C Synergistic combination
05/25/2005CN1202861C Use of compound interferon in treating SARS disease
05/25/2005CN1202834C Application of effective part of Chinese medicinal material lindley eupatorium herb in preparing antiviral medicine
05/25/2005CN1202831C Macrolide formulations for inhalation and use thereof
1 ... 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 ... 878